Applied Therapeutics Inc. (APLT) Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at WCIRDC

Applied Therapeutics Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of data at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles (December 4-7, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM).

“The Aldose Reductase enzyme has long been known to play a key role in several diabetic complications, including DbCM," said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. "Unfortunately, past attempts to inhibit Aldose Reductase failed due to lack of selectivity and off-target toxicity. AT-001 was designed based on new structural understanding of the AR enzymatic site, resulting in significantly increased potency and selectivity. The pre-clinical data we are presenting at WCIRDC shows the head to head comparison of AT-001 vs. a first-generation Aldose Reductase inhibitor and highlights the improvements over these prior ARIs.”

Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy (#068)
(poster presentation Thursday, Dec 5th, from 6:30-7:30pm; oral presentation Friday, Dec 6th, from 6:45-8:15pm)

• AT-001 is logarithmically more potent than zopolrestat in inhibiting Aldose Reductase
• The unique structure and activity of AT-001 provide selectivity for Aldose Reductase and avoid off-target inhibition of Aldehyde Reductase
• The in vitro safety of this agent together with the positive safety data from the phase 1/2 program, support the ongoing pivotal study in DbCM

The presentation will be available on the Applied Therapeutics website following the oral session.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Rubrik, Inc. (RBRK) IPO Opens at $38.60, Priced at $32
• Century Communities (CCS) Files Mixed Shelf